MacroGenics Sets Date for First Quarter 2024 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a leading biopharmaceutical company specializing in antibody-based therapeutics for cancer treatment, is set to release its financial results for the first quarter of 2024 on Thursday, May 9, 2024. The company will host a conference call at 4:30 pm ET on the same day to discuss the financial results and recent corporate progress.

To participate in the conference call, interested individuals can register in advance via a provided link. Upon registration, participants will receive a confirmation email with the dial-in number, unique passcode, and registrant ID needed to join the call. Additionally, a listen-only webcast of the conference call will be available on the Investor Relations section of MacroGenics’ website.

MacroGenics is known for its focus on developing innovative monoclonal antibody-based therapeutics for cancer treatment. The company leverages its proprietary technology platforms to generate a pipeline of promising product candidates and has established strategic collaborations with global pharmaceutical and biotechnology companies.

For more information about MacroGenics, interested parties can visit the company’s website at www.macrogenics.com. The upcoming conference call and financial results release are highly anticipated events within the biopharmaceutical industry, as stakeholders look forward to hearing about the company’s progress and future prospects.